Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.
Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, Galley L, Karnasuta C, Kim SR, Robb ML, Michael NL, Kibuuka H, Wabwire-Mangen F, Graham BS, Birx DL, de Souza MS, Cox JH. Eller MA, et al. Among authors: cox jh. Vaccine. 2007 Nov 7;25(45):7737-42. doi: 10.1016/j.vaccine.2007.08.056. Epub 2007 Sep 17. Vaccine. 2007. PMID: 17920731 Clinical Trial.
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand. Karnasuta C, et al. Among authors: cox jh. Vaccine. 2005 Mar 31;23(19):2522-9. doi: 10.1016/j.vaccine.2004.10.028. Vaccine. 2005. PMID: 15752839 Clinical Trial.
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML. Kibuuka H, et al. Among authors: cox jh. J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299. J Infect Dis. 2010. PMID: 20078213 Free PMC article. Clinical Trial.
Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.
Olemukan RE, Eller LA, Ouma BJ, Etonu B, Erima S, Naluyima P, Kyabaggu D, Cox JH, Sandberg JK, Wabwire-Mangen F, Michael NL, Robb ML, de Souza MS, Eller MA. Olemukan RE, et al. Among authors: cox jh. Clin Vaccine Immunol. 2010 Jun;17(6):910-8. doi: 10.1128/CVI.00492-09. Epub 2010 Mar 3. Clin Vaccine Immunol. 2010. PMID: 20200187 Free PMC article.
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B. Gudmundsdotter L, et al. Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29. Vaccine. 2009. PMID: 19450644 Free PMC article. Clinical Trial.
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.
Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH. Earl PL, et al. Among authors: cox jh. Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3. Vaccine. 2009. PMID: 19654066 Free PMC article.
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC. Cox JH, et al. Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9. Vaccine. 2012. PMID: 22234262 Free PMC article.
Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, Michael NL, Jagodzinski L, Hawkes C, Mayers D, Gilliam BL, Birx DC, Robb ML. Kim JH, et al. Among authors: cox jh. AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1021-34. doi: 10.1089/088922201300343708. AIDS Res Hum Retroviruses. 2001. PMID: 11485619
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G; HIV Immunogenicity Study 01/02 Team. Sandström E, et al. J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507. J Infect Dis. 2008. PMID: 18808335 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH. O'Connell RJ, et al. Among authors: cox j. J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11. J Infect Dis. 2016. PMID: 26908741 Free PMC article. Clinical Trial.
217 results